Houston-based Procyrion develops a catheter-deployed percutaneous mechanical circulatory support (pMCS) device called Aortix.
The company designed the device to treat patients with acute decompensated heart failure (ADHF) who remain congested despite standard medical therapy (cardiorenal syndrome or CRS). Procyrion enrolled the first patient in its DRAIN-AF pivotal IDE trial in November 2023. The company also raised nearly $60 million to support the device last year.
Aortix aims to directly increase kidney perfusion while unloading the heart and improving cardiac performance. The device uses fluid entrainment to pump blood without the need for a valve, delivering a therapeutic benefit via a physiologically natural mechanism of action for people with acute decompensated heart failure who remain congested despite standard medical therapy (cardiorenal syndrome or CRS).
“I’m honored to join Procyrion to advance the important work already underway,” said Davis. “Patients with diuretic-resistant heart failure urgently need new options and the Aortix pump offers a compelling, new approach. I look forward to collaborating with the team and clinicians at our clinical sites to expand understanding of our therapy and to lay the groundwork in support of future commercialization.”
More about new Procyrion CCO Andrew Davis
Davis previously served as CCO at Silk Road Medical, which Boston Scientific acquired in 2024. There, he successfully spearheaded the go-to-market strategy for the company’s transcarotid artery revascularization (TCAR) therapy. He joins the company more than a year after former Silk Road colleague, the company’s COO Lucas Buchanan, joined Procyrion’s board.
Prior to Silk Road, Davis spent 15 years at Medtronic. There, he led multiple sales organizations across Cardiac and Vascular Therapies, including TAVR, endovascular, peripheral vascular and spine/biologics. Additionally, Davis spent time in senior commercial roles at Endologix and with 3M’s Advanced Wound Therapy group.
“Andy’s deep cardiovascular experience and proven track record of launching category-creating therapies makes him an exceptional addition to the company as enrollment in our DRAIN-HF pivotal trial continues to positively progress,” said Dr. Eric S. Fain, president and CEO of Procyrion. “Patients with diuretic-resistant heart failure who have failed currently available therapies remains a significant unmet need and an underserved, large market opportunity. Andy’s leadership will be instrumental as we strengthen therapy development efforts and build the foundation needed to bring the Aortix pump to patients and physicians.”
